查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012946

牛呼吸道疾病治療藥物市場：按產品類型、給藥途徑、目標動物和分銷管道分類的全球市場預測，2026-2032年

Bovine Respiratory Disease Treatment Market by Product Type, Route Of Administration, Animal Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，牛呼吸道疾病治療市場價值將達到 22.3 億美元，到 2026 年將成長至 23.7 億美元，到 2032 年將達到 38.4 億美元，複合年成長率為 8.05%。

主要市場統計數據
基準年 2025 22.3億美元
預計年份：2026年 23.7億美元
預測年份 2032 38.4億美元
複合年成長率 (%) 8.05%

治療牛呼吸系統疾病的策略方法：使治療方法方案與臨床實際情況、監管趨勢和營運重點保持一致。

牛呼吸道疾病仍然是全球畜牧業面臨的最持久、最具經濟影響的健康挑戰之一。本文將讀者置於臨床實務、藥物研發和供應鏈演變的交會點，揭示臨床因素、監管壓力和生產經濟如何相互作用，共同塑造治療策略。此疾病群包含病毒和細菌病原體，通常需要綜合治療和預防措施。此外，抗生素和疫苗的相互作用在任何有效的控制方案中都起著至關重要的作用。

科學創新、管理方法的進步以及分銷系統的重組如何重塑治療策略和臨床實踐的範式？

牛呼吸道疾病的治療格局正在經歷一場變革，這主要得益於科學創新、監管改革和生產方式的轉變。疫苗技術和製劑科學的進步，透過開發專門針對主要病毒和細菌病原體的去活化疫苗和減毒活病毒疫苗平台，正在拓展預防選擇。同時，抗生素分類和給藥策略的改進，正推動在不影響臨床患病動物治療效果的前提下，合理使用抗菌藥物的目標不斷實現。

近期關稅政策更新對供應鏈、採購慣例以及牛健康管理中基本治療藥物的持續獲取的實際影響。

美國2025年前的關稅政策發展正在影響整個動物保健生態系統的供應鏈決策、籌資策略和成本結構。進口關稅和海關程序的變化正在影響成品藥、疫苗成分和活性成分的分銷，迫使製造商和經銷商重新評估籌資策略和庫存佈局，以維持供應的連續性。擁有複雜全球供應鏈的公司被迫考慮近岸外包、雙重採購和策略儲備等措施，以減輕關稅帶來的衝擊。

從治療領域、給藥途徑、目標動物特徵和通路與臨床和商業策略之間進行詳細的細分觀點。

細分市場分析揭示了每種產品類別、給藥途徑、動物種類和通路的不同機會和臨床考慮。在產品類型方面，抗生素包括不同的藥理學家族，例如BETA-內醯胺類、Fluoroquinolones、大環內酯類和四環黴素，其中大環內酯類又包括胸苷黴素、曲曲霉素和泰樂菌素等藥物。疫苗屬於預防領域，分為去活化疫苗和減毒活疫苗。去活化疫苗針對牛呼吸道融合細胞病毒（BRSV）、巴氏桿菌和副流感病毒3型（PI3）等病原體；減毒活病毒疫苗也針對BRSV、曼氏桿菌和PI3。每種疫苗的免疫抗原性特徵和對低溫運輸的影響各不相同。

區域生產系統、法規環境和分銷基礎設施如何塑造差異化的治療方法和實施策略。

區域趨勢影響著美洲、歐洲、中東和非洲以及亞太地區的臨床重點、監管預期和分銷策略。在美洲，生產系統涵蓋大規模商業育肥場到家庭式酪農，由此產生了多樣化的治療需求，因此管理計劃和可追溯性備受重視。疫苗宣傳活動和針對性抗生素計劃透過獸醫網路和一體化供應鏈進行協調，飼料廠和獸醫診所在產品分銷中發揮著至關重要的作用。

為了因應臨床需求和供應鏈挑戰，各公司正專注於策略應對措施，重點在於配方創新、通路夥伴關係和診斷整合。

主要企業洞察凸顯了行業相關人員如何應對臨床需求、日益複雜的供應鏈以及不斷演變的分銷模式。領先的研發和供應公司正投資於製劑創新，以最佳化穩定性、減少對低溫運輸的依賴，並拓展口服和鼻腔給藥途徑，從而實現大劑量給藥。其他公司則在繼續支持符合藥品管理指南和標籤最佳化的同時，改進其注射劑產品組合，以增強藥物動力學特性並提高給藥便利性。

為製造商和經銷商提供實際有效的措施，以加強管理、供應鏈韌性以及農場治療藥物和疫苗的供應。

針對行業領導者的實際建議著重於使產品系列與管理目標保持一致、增強供應鏈韌性以及改善終端用戶的獲取途徑。優先考慮平衡治療方案和預防平台的產品組合策略，投資於能夠降低疾病發生率的疫苗技術和支持符合管理原則的抗生素製劑。同時，應擴大給藥途徑的開發，例如鼻腔給藥和飼料/飲水中的口服給藥，以減輕操作負擔並促進群體層面的干涉措施。

透過嚴謹且多方面的研究途徑，結合對第一線臨床醫生的訪談、供應鏈分析和文獻整合，獲得了切實可行的臨床和商業性見解。

本報告的調查方法透過整合多方面證據、專家訪談和情境分析，確保了其可靠性和可操作性。為了了解實際操作和採購行為，我們對臨床醫生、動物健康專家、飼料廠經理和分銷主管進行結構化訪談，並將訪談作為主要資訊來源。這些定性研究結果與疫苗平台、抗生素分類和給藥科學的專家文獻進行了交叉比對，以確保臨床準確性並闡明其對營運的影響。

一份簡潔、全面的分析報告強調，綜合預防、以管理主導的治療和供應鏈適應性是永續疾病管理的基礎。

總之，有效管理牛呼吸道疾病需要綜合策略，該策略應結合治療方法創新、實用給藥方法和完善的配送體系。疫苗技術和藥物科學的進步提供了有效的預防措施，而精細的抗生素策略和合理的用藥規範則能維持臨床病例的治療效果。給藥途徑的選擇必須考慮農場的實際情況、不同動物（如牛、牛和牛）的具體情況以及現有通路的限制。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：牛隻呼吸系統疾病治療市場：依產品類型分類

  • 抗生素
    • BETA-內醯胺
    • Fluoroquinolones
    • 大環內酯類
      • 奇爾米考辛
      • 麴菌
      • 泰樂菌素
    • 四環黴素
  • 疫苗
    • 失活
      • BRSV
      • 巴斯德氏菌
      • PI3
    • 活病毒疫苗
      • BRSV
      • 曼海姆
      • PI3

第9章：牛呼吸系統疾病治療藥物市場：依給藥途徑分類

  • 注射藥物
    • 肌肉內部
    • 靜脈
    • 皮下
  • 鼻內
  • 口服
    • 飼料
    • 水

第10章：牛呼吸系統疾病治療市場：依動物類型分類

  • 牛
    • 牛
    • 牛
  • 牛
    • 牛牛犢
    • 乳牛
  • 小母牛

第11章：牛隻呼吸系統疾病治療市場：依分銷管道分類

  • 飼料廠
    • 商業麵粉廠
    • 農場自有麵粉廠
  • 網路藥房
    • 動物用藥品平台
    • 一般電子商務零售
  • 動物醫院
    • 獨立動物醫院
    • 大型診所

第12章：牛隻呼吸系統疾病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：牛隻呼吸系統疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：牛隻呼吸系統疾病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國牛呼吸系統疾病治療市場

第16章：中國牛隻呼吸系統疾病治療藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aratana Therapeutics, Inc.
  • Ashish Life Science Pvt. Ltd.
  • Bimeda Inc.
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Huvepharma AD
  • IDEXX Laboratories, Inc.
  • India Immunologicals Ltd.
  • Inovio Pharmaceuticals, Inc.
  • Intas Pharmaceuticals Ltd.
  • Kyoritsu Seiyaku Corporation
  • Med-Pharmex Ltd.
  • Merck & Co., Inc.
  • Neogen Corporation
  • Novartis Animal Health
  • Ourofino Saude Animal SA
  • Phibro Animal Health Corporation
  • Plumbline Life Sciences
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
  • Zydus Animal Health and Investments Limited
Product Code: MRR-437D4595869F

The Bovine Respiratory Disease Treatment Market was valued at USD 2.23 billion in 2025 and is projected to grow to USD 2.37 billion in 2026, with a CAGR of 8.05%, reaching USD 3.84 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.23 billion
Estimated Year [2026] USD 2.37 billion
Forecast Year [2032] USD 3.84 billion
CAGR (%) 8.05%

A strategic orientation to bovine respiratory disease treatment that aligns therapeutic choices with clinical realities, regulatory dynamics, and operational priorities

Bovine respiratory disease remains one of the most persistent and economically significant health challenges in cattle production systems globally. This introduction situates the reader at the intersection of clinical practice, pharmaceutical development, and supply chain evolution, highlighting how clinical drivers, regulatory pressures, and production economics collectively shape treatment strategies. The disease complex itself encompasses viral and bacterial etiologies that frequently require integrated therapeutic and preventive responses, and the interplay between antibiotics and vaccines is central to any effective control program.

Clinicians and herd managers increasingly rely on evidence-based protocols that balance animal welfare, antimicrobial stewardship, and operational efficiency. In this context, treatment selection is influenced by pathogen prevalence, animal category, route of administration suitability, and distribution channel accessibility. The landscape has been further complicated by shifting regulations and growing emphasis on reduced antimicrobial use, which amplifies the role of targeted vaccination programs and alternative delivery modalities.

This introduction therefore frames the subsequent analysis around four core dimensions: therapeutic modalities and formulations, administration routes and on-farm logistics, animal demographic considerations, and distribution ecosystems. By grounding the discussion in these pillars, readers will gain a practical orientation that supports strategic decisions in product development, clinical implementation, and commercial planning.

How scientific innovation, evolving administration methods, and distribution reconfiguration are reshaping treatment strategies and clinical practice paradigms

The treatment landscape for bovine respiratory disease is undergoing transformative shifts driven by scientific innovation, regulatory recalibration, and changing production practices. Advances in vaccine technology and formulation science are enabling broader preventive options, with inactivated and live attenuated platforms tailored to protect against core viral and bacterial agents. At the same time, refinement of antibiotic classes and dosing strategies is advancing antimicrobial stewardship objectives without sacrificing therapeutic potency for clinically ill animals.

Equally consequential are shifts in administration practices. Injectable delivery remains central to rapid systemic therapy, but intranasal vaccines and oral delivery via feed or water are gaining practical traction because they simplify mass administration and reduce handling stress. These changes intersect with animal demographics: protocols differ substantively between adult cattle populations, which include distinct beef and dairy management considerations, and younger cohorts such as beef calves and dairy calves where immune maturity and management systems affect both prevention and treatment timing.

Distribution systems are evolving in parallel. Traditional veterinary clinic channels continue to deliver clinical oversight and prescription-based treatments, yet feed mills-both commercial and onfarm-and online animal health platforms are reshaping access and procurement behaviors. Together, these trends are reconfiguring go-to-market strategies for product developers and suppliers, prompting new partnerships across pharmaceutical, feed, and veterinary service providers.

The practical ramifications of recent tariff policy updates on supply chains, procurement practices, and continuity of access for essential therapies in cattle health

Tariff policy developments in the United States for 2025 have influenced supply chain decisions, procurement tactics, and cost structures across the animal health ecosystem. Changes to import duties and customs protocols affect the flow of finished pharmaceuticals, vaccine components, and active ingredients, prompting manufacturers and distributors to reassess sourcing strategies and inventory positioning to preserve continuity of supply. Firms with complex global supply chains have been compelled to evaluate nearshoring, dual-sourcing, and strategic stockpiling as mitigants against tariff-driven disruptions.

These shifts have downstream effects on stakeholders from feed mill operators to veterinary clinics. Feed mills sourcing medicated premixes and onfarm mills procuring therapeutics now face altered landed costs that can impact the pricing and availability of oral medications administered via feed or water. Similarly, online animal health platforms and general eRetailers importing niche formulations may adjust catalog offerings to manage margin pressures or compliance complexity. For animal producers, the practical implication is increased attention to procurement timelines and supplier reliability, as well as a renewed focus on preventive measures such as vaccination campaigns that reduce reliance on imported therapeutic products.

Regulatory harmonization and trade facilitation efforts remain important variables. Where tariff changes create friction, collaborative industry responses-such as pooled procurement, supplier diversification, and local formulation development-are emerging as pragmatic adaptations. These responses prioritize uninterrupted access to essential therapies and vaccines while maintaining adherence to clinical protocols and stewardship commitments.

An in-depth segmentation perspective linking therapeutic categories, administration routes, animal demographics, and distribution pathways to clinical and commercial strategies

Segmentation insights reveal differentiated opportunities and clinical considerations across product classes, administration routes, animal types, and distribution pathways. Within product type, antibiotics encompass distinct pharmacological families including beta lactams, fluoroquinolones, macrolides, and tetracyclines, with macrolides further represented by agents such as tilmicosin, tulathromycin, and tylosin. Vaccines occupy preventive space and are stratified into inactivated platforms targeting pathogens like bovine respiratory syncytial virus, Pasteurella and parainfluenza 3, and live attenuated formulations that also target BRSV, Mannheimia, and PI3, each with different immunogenic profiles and cold-chain implications.

Route of administration is a pivotal segmentation lens: injectable therapies are administered intramuscularly, intravenously or subcutaneously and remain the standard when systemic concentrations and rapid onset are required. Intranasal delivery offers localized immune priming especially valuable in young stock, while oral routes administered through feed or water enable mass medication strategies that reduce handling but require careful dosing control and palatability considerations. Animal type further differentiates clinical protocols; adult cattle populations, encompassing both beef and dairy cattle, have distinct production objectives and stewardship constraints compared with calves and heifers where immune competence and management system vulnerability influence timing and regimen selection. Calves in beef and dairy systems may necessitate earlier preventive interventions and tailored therapeutic approaches.

Distribution channel segmentation highlights the service and logistics dimension. Feed mills-both commercial and onfarm-play a role in delivering medicated feeds and supporting oral administration strategies. Online pharmacies operate as animal health platforms and generalized eRetail channels, broadening access to products where regulatory frameworks permit. Veterinary clinics, from independent practices to large multi-site groups, continue to provide clinical oversight, diagnostics, and prescription-based therapies. Understanding these intersecting segments enables stakeholders to align product development, packaging, cold-chain design, and commercial models with end-user requirements and operational realities.

How regional production systems, regulatory environments, and distribution infrastructures are shaping differentiated treatment approaches and deployment strategies

Regional dynamics shape clinical priorities, regulatory expectations, and distribution strategies across the Americas, Europe, Middle East & Africa, and the Asia-Pacific. In the Americas, production systems span large-scale commercial feedlots to family-run dairy operations, yielding diverse treatment needs and a strong emphasis on stewardship programs and traceability. Vaccination campaigns and targeted antibiotic regimens are coordinated through veterinary networks and integrated supply chains, with feed mills and veterinary clinics playing prominent roles in product distribution.

Within Europe, Middle East & Africa, regulatory frameworks and stewardship initiatives often drive conservative antibiotic use and increased adoption of preventive strategies. This region demonstrates variable infrastructure capacity, from highly developed cold-chain systems in parts of Europe to more fragmented distribution networks in some Middle Eastern and African markets, which influences the practical adoption of live attenuated vaccines and injectable formulations. The Asia-Pacific region is characterized by rapid growth in intensive production systems, diverse regulatory environments, and an expanding role for online animal health platforms and commercial feed mills. In many Asia-Pacific markets, the scale of production and proximity to manufacturing hubs create unique logistics advantages and challenges, particularly around feed- and water-administered therapies.

Across regions, the practical implications for stakeholders include alignment of product formats with logistical realities, sensitivity to regulatory and stewardship frameworks, and tailoring of commercial approaches to local procurement behaviors. Cross-regional knowledge transfer and adaptive implementation strategies are therefore essential for successful deployment of therapeutics and preventive programs.

Strategic corporate responses highlighting formulation innovation, channel partnerships, and diagnostic integration to meet clinical needs and supply chain challenges

Key company insights emphasize how industry participants are responding to clinical demands, supply chain complexity, and shifting distribution models. Leading developers and suppliers are investing in formulation innovation to optimize stability, reduce cold-chain dependency, and expand oral and intranasal options that facilitate mass administration. Others are refining injectable portfolios to improve pharmacokinetic profiles and dosing convenience, while continuing to support stewardship-aligned guidance and label optimization.

Strategic partnerships are increasingly important; collaborations between pharmaceutical firms, feed producers, and veterinary service providers enable integrated solutions that align therapeutic products with onfarm delivery capabilities. Companies with diversified distribution networks, including relationships with commercial and onfarm feed mill operators, online animal health platforms, and both independent and large veterinary practices, are better positioned to manage channel-specific demands and regulatory nuances. Additionally, manufacturers addressing tariff and supply continuity challenges are exploring regional manufacturing and contract manufacturing arrangements to shorten supply lines and enhance responsiveness.

innovation in diagnostics and data-driven health management is another focal area, as companies that integrate diagnostic support with product offerings help clinicians implement targeted therapies and measure intervention outcomes. The commercial implication is that companies combining therapeutic breadth, distribution agility, and diagnostic enablement can differentiate by delivering both clinical value and operational efficiencies to producers and veterinarians.

Practical, high-impact steps for manufacturers and distributors to strengthen stewardship, supply chain resilience, and on-farm accessibility of treatments and vaccines

Actionable recommendations for industry leaders focus on aligning product portfolios with stewardship goals, strengthening supply chain resilience, and enhancing end-user accessibility. Prioritize portfolio strategies that balance therapeutic options and preventive platforms, investing in vaccine technologies that reduce disease incidence and in formulations that support stewardship-compliant antibiotic use. Simultaneously, expand development into administration modalities such as intranasal and oral feed or water delivery to lower handling burdens and facilitate herd-level interventions.

Operationally, pursue supply chain diversification and nearshoring where feasible to mitigate tariff exposure and ensure uninterrupted access to critical raw materials and finished products. Strengthen partnerships with feed mills, online animal health platforms, and veterinary networks to create integrated procurement pathways that reflect how producers obtain therapeutics and vaccines in practice. Invest in cold-chain optimization where live attenuated vaccines demand stricter temperature control, while exploring formulation stability enhancements that reduce dependency on complex logistics.

Commercially, develop education and stewardship programs aimed at veterinarians and producers that emphasize diagnostic-led treatment, appropriate route selection, and age- and production-specific protocols for adult cattle, calves, and heifers. Leverage diagnostic tools and data analytics to demonstrate intervention outcomes, and design pricing and access models that support both smallholder and large-scale operations to maximize adoption and clinical impact.

A rigorous, multi-source research approach combining frontline clinician interviews, supply chain mapping, and literature synthesis to produce actionable clinical and commercial insights

The research methodology underpinning this report integrates multi-source evidence synthesis, expert consultation, and scenario-based analysis to ensure robustness and practical relevance. Primary inputs included structured interviews with clinicians, herd health specialists, feed mill managers, and distribution executives to capture frontline practices and procurement behaviors. These qualitative insights were triangulated with technical literature on vaccine platforms, antibiotic classes, and administration science to ensure clinical accuracy and to contextualize operational implications.

Secondary sources comprised peer-reviewed journals, regulatory guidance documents, and publicly available industry reports that elucidate therapeutic mechanisms, stewardship frameworks, and logistics considerations. The methodology also applied supply chain mapping to understand sourcing pathways for active pharmaceutical ingredients, formulation components, and finished goods, allowing identification of potential chokepoints and adaptive strategies in response to tariff changes. Analytical frameworks emphasized translational relevance, focusing on actionable insights for product development, distribution strategy, and clinical implementation rather than quantitative market projections.

Throughout the research process, findings were validated by cross-checking clinician perspectives against veterinary practice guidelines and by obtaining feedback from distribution channel stakeholders to ensure that recommendations reflect real-world constraints and opportunities.

A concise synthesis emphasizing integrated prevention, stewardship-led therapeutics, and supply chain adaptability as the foundation for durable disease control

In conclusion, effective management of bovine respiratory disease requires integrated strategies that bridge therapeutic innovation, administration practicality, and resilient distribution models. Advancements in vaccine technology and formulation science provide meaningful preventive options, while refined antibiotic strategies and stewardship practices preserve therapeutic effectiveness for clinical cases. The choice of administration route must reflect operational realities on farm, individual animal factors such as adult cattle, calves, and heifers, and the constraints of available distribution channels.

Supply chain dynamics, including the implications of tariff adjustments, underscore the importance of diversification and regional adaptability. Companies that align product design with logistical capabilities-such as injectable formats, intranasal options, and oral feed- and water-administered therapies-will be better positioned to support veterinarians and producers across varied regional contexts. Finally, collaboration across pharmaceutical developers, feed suppliers, diagnostic providers, and veterinary networks is essential to deliver clinically sound, operationally feasible, and stewardship-aligned solutions that improve herd health outcomes and sustain long-term therapeutic efficacy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bovine Respiratory Disease Treatment Market, by Product Type

  • 8.1. Antibiotics
    • 8.1.1. Beta Lactams
    • 8.1.2. Fluoroquinolones
    • 8.1.3. Macrolides
      • 8.1.3.1. Tilmicosin
      • 8.1.3.2. Tulathromycin
      • 8.1.3.3. Tylosin
    • 8.1.4. Tetracyclines
  • 8.2. Vaccines
    • 8.2.1. Inactivated
      • 8.2.1.1. BRSV
      • 8.2.1.2. Pasteurella
      • 8.2.1.3. PI3
    • 8.2.2. Live Attenuated
      • 8.2.2.1. BRSV
      • 8.2.2.2. Mannheimia
      • 8.2.2.3. PI3

9. Bovine Respiratory Disease Treatment Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
    • 9.1.3. Subcutaneous
  • 9.2. Intranasal
  • 9.3. Oral
    • 9.3.1. Feed
    • 9.3.2. Water

10. Bovine Respiratory Disease Treatment Market, by Animal Type

  • 10.1. Adult Cattle
    • 10.1.1. Beef Cattle
    • 10.1.2. Dairy Cows
  • 10.2. Calves
    • 10.2.1. Beef Calves
    • 10.2.2. Dairy Calves
  • 10.3. Heifers

11. Bovine Respiratory Disease Treatment Market, by Distribution Channel

  • 11.1. Feed Mills
    • 11.1.1. Commercial Mills
    • 11.1.2. Onfarm Mills
  • 11.2. Online Pharmacies
    • 11.2.1. Animal Health Platforms
    • 11.2.2. General ERetail
  • 11.3. Veterinary Clinics
    • 11.3.1. Independent Clinics
    • 11.3.2. Large Practices

12. Bovine Respiratory Disease Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bovine Respiratory Disease Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bovine Respiratory Disease Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Bovine Respiratory Disease Treatment Market

16. China Bovine Respiratory Disease Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Aratana Therapeutics, Inc.
  • 17.6. Ashish Life Science Pvt. Ltd.
  • 17.7. Bimeda Inc.
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Ceva Sante Animale S.A.
  • 17.10. Dechra Pharmaceuticals PLC
  • 17.11. Elanco Animal Health Incorporated
  • 17.12. Huvepharma AD
  • 17.13. IDEXX Laboratories, Inc.
  • 17.14. India Immunologicals Ltd.
  • 17.15. Inovio Pharmaceuticals, Inc.
  • 17.16. Intas Pharmaceuticals Ltd.
  • 17.17. Kyoritsu Seiyaku Corporation
  • 17.18. Med-Pharmex Ltd.
  • 17.19. Merck & Co., Inc.
  • 17.20. Neogen Corporation
  • 17.21. Novartis Animal Health
  • 17.22. Ourofino Saude Animal S.A.
  • 17.23. Phibro Animal Health Corporation
  • 17.24. Plumbline Life Sciences
  • 17.25. Vetoquinol S.A.
  • 17.26. Virbac S.A.
  • 17.27. Zoetis Inc.
  • 17.28. Zydus Animal Health and Investments Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LARGE PRACTICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LARGE PRACTICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LARGE PRACTICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 278. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 284. AS